Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab in high-risk smoldering multiple myeloma
2011-001735-22Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in smoldering multiple myeloma (SMM) comparing Siltuximab with Placebo (2 arms). Primary endpoint: One-year progression-free survival rate. Started Aug 2011; status: completed.
02
Drugs
siltuximab
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on 2011-001735-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001735-22.